ArticleNeuroreport2025
Astaxanthin reverses neurodevelopmental impairment by decreasing oxidative stress-induced disruption of Maf/Bcl2 signaling in prenatal alcohol exposure.
Article in Neuroreport, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- PDE4A knockdown rescues alcohol-induced cognitive impairment and synaptic dysfunction via the cAMP/PKA/CREB pathway.The international journal of neuropsychopharmacology · 2026Article
- Therapeutic Potential of Astaxanthin for Body Weight Regulation: A Systematic Review and Meta-Analysis with Dose-Response Assessment.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPrenatal alcohol exposure (PAE) is recognized as the leading cause of adverse prenatal exposure disorders worldwide. The neurodevelopmental impairments resulting from PAE in offspring are classified under fetal alcohol syndrome (FAS). Nonetheless, the precise underlying pathogenic mechanisms of FAS remain incompletely understood, and effective therapeutic interventions are currently lacking. Notably, the antioxidant astaxanthin has demonstrated significant neuroprotective properties.
methodsIn this study, we established a C57BL/6J mouse model of FAS and administered potential therapeutic doses of astaxanthin through oral gavage. We evaluated the dual effects of ethanol exposure and astaxanthin intervention on oxidative stress, cognitive development, and cellular apoptosis in FAS. Furthermore, using molecular detection and plasmid transfection, we validated the regulatory cascade between the transcription factor Maf and the antiapoptotic protein B-cell lymphoma 2 (Bcl2), demonstrating the therapeutic efficacy and mechanism of astaxanthin against FAS.
resultsThe results demonstrate that prenatal alcohol exposure induces neuronal oxidative damage and cognitive developmental impairments, concomitant with reduced expression of the transcription factor Maf in the brain and consequent suppression of antiapoptotic Bcl2 activity. Strikingly, astaxanthin administration significantly attenuated alcohol-induced reactive oxygen species accumulation and restored both Maf and Bcl2 expression levels. This intervention effectively ameliorated neuronal apoptosis and neurodevelopmental abnormalities.
conclusionThese findings reveal that astaxanthin alleviates FAS-related pathophysiology by rescuing the alcohol-disrupted Maf-Bcl2 axis, consequently reducing neuronal cell death. This study provides novel mechanistic insights into FAS pathogenesis and identifies a promising therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.